The new prospects of the inhalation therapy for bronchial asthma
https://doi.org/10.18093/0869-0189-2020-30-4-473-484
Abstract
Based on the latest new international literature data, the article considers the possibilities of fixed combinations of long-acting β2-agonist, long-acting muscarinic antagonist and inhaled corticosteroids in achieving the control of bronchial asthma (BA). Clinical advantages for a fixed combination of indacaterol, glycopyrronium and mometasone furoate one dosing regimen in the therapy of BA are presented based on the results of recently completed randomized clinical trials IRIDIUM and ARGON.
About the Authors
S. N. Avdeev
I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia;
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Sergey N. Avdeev, Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
ul. Trubetskaya 8, build. 2, Moscow, 119991,
Orekhovyy bul'var 28, Moscow, 115682
Z. R. Aisanov
N.I.Pirogov Federal Russian National Research Medical University, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Zaurbek R. Aisanov, Doctor of Medicine, Professor, Department of Pulmonology
ul. Ostrovityanova 1, Moscow, 117997
References
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2020. Available at: https://ginasthma.org [Accessed: August 07, 2020].
2. Beasley R., Harper J., Bird G. et al. Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am. J. Respir. Crit. Care Med. 2019; 199 (12): 1471–1477. DOI: 10.1164/rccm.201810-1868CI.
3. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844. DOI: 10.1164/rccm.200401-033OC.
4. Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim. Care Respir. Med. 2014; 24: 24009. DOI: 10.1038/npjpcrm.2014.9.
5. Hansen R., Seifeldin R., Noe L. Medication adherence in chronic disease: issues in posttransplant immunosuppression. Transplant. Proc. 2007; 39 (5): 1287–1300. DOI: 10.1016/j.transproceed.2007.02.074.
6. Fink J.B., Rublin B.K. Problem with inhaler use: a call for improved clinician and patient education. Respir. Care. 2005; 50 (10): 1360–1374.
7. Kew K.M., Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst. Rev. 2016; (1): CD011721. DOI: 10.1002/14651858.CD011721.pub2.
8. Barnes P.J. Distribution of receptor targets in the lung. Proc. Am. Thorac. Soc. 2004; 1 (4): 345–351. DOI: 10.1513/pats.200409-045MS.
9. Gwilt C.R., Donnelly L.E., Rogers D.F. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol. Ther. 2007; 115 (2): 208–222. DOI: 10.1016/j.pharmthera.2007.05.007.
10. Price D., Fromer L., Kaplan A. et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim. Care Respir. Med. 2014; 24: 14023. DOI: 10.1038/npjpcrm.2014.23.
11. Grainge C.L., Lau L.C.K., Ward J.A. et al. Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364 (21): 2006–2015. DOI: 10.1056/NEJMoa1014350.
12. Kerstjens H.A.M., Maspero J., Chapman K.R. et al. Oncedaily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. [Published online: July 9, 2020]. Lancet Respir. Med. 2020; S2213-2600(20)30190-9. DOI: 10.1016/S2213-2600(20)30190-9.
13. Gessner C., Kornmann O., Maspero J. et al. Fixed-dose combination of indacaterol/glycopyrronium/ mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respir. Med. 2020; 170: 106021. DOI: 10.1016/j.rmed.2020.106021.
14. Fausnight T., Craig T. Mometasone furoate dry powder inhaler for the treatment of asthma. Exp. Opin. Pharma - cother. 2011; 12 (17): 2707–2712. DOI: 10.1517/14656566.2011.630390.
15. Juniper E.F., Bousquet J., Abetz L., Bateman E.D. Identifying “well-controlled” and “not well-controlled” asthma using the Asthma Control Questionnaire. Respir. Med. 2006; 100 (4): 616–621. DOI: 10.1016/j.rmed.2005.08.012.
16. Papi A., Humbert M., Kostikas K. et al. Medium-dose indacaterol/glycopyrronium/mometasone furoate fixed-dose combination improves lung function compared with highdose indacaterol/mometasone furoate and salmeterol/fluticasone and reduces exacerbation rates versus high-dose salmeterol/fluticasone in moderate-to-severe asthma: the IRIDIUM study. Am. J. Respir. Crit. Care Med. 2020; 201: A3008. DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3008.
17. Price D., Robertson A., Bullen K. et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm. Med. 2010; 10: 1. DOI: 10.1186/1471-2466-10-1.
18. Virchow J.C., Kuna P., Paggiaro P. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRI-MARAN and TRIGGER): two double-blind, parallelgroup, randomised, controlled phase 3 trials. Lancet. 2019; 394 (10210): 1737–1749. DOI: 10.1016/S0140-6736(19)32215-9.
19. Pavord I., Peachey G., Kerstjens H. et al. Once-daily, sing - le-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study. J. Allergy Clin. Immunol. 2020; 145 (2, Suppl.): AB241. DOI: 10.1016/j.jaci.2019.12.141.
20. Juniper E.F., Buist A.C., Cox F.V. et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999; 115 (5): 1265–1270. DOI: 10.1378/chest.115.5.1265.
21. Kornmann O., Dahl R., Centanni S. et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebocontrolled comparison. Eur. Respir. J. 2011; 37 (2): 273–279. DOI: 10.1183/09031936.00045810.
22. Kerwin E., Hebert J., Gallagher N. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 2012; 40 (5): 1106–1114. DOI: 10.1183/09031936.00040712.
23. Donohue J.F., Betts K.A., Du E. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 367–381. DOI: 10.2147/COPD.S119908.
24. Yang D., Wang J., Bunjhoo H. et al. Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysis. Asian. Pac. J. Allergy Immunol. 2012; 31 (1): 26–35.
25. Derendorf H., Nave R., Drollmann A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28 (5): 1042– 1050. DOI: 10.1183/09031936.00074905.
26. Valotis A., Hogger P., Neukam K., Elert O. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J. Pharm. Sci. 2004; 93 (5): 1337–1350. DOI: 10.1002/jps.20049
Review
For citations:
Avdeev S.N., Aisanov Z.R. The new prospects of the inhalation therapy for bronchial asthma. PULMONOLOGIYA. 2020;30(4):473-484. (In Russ.) https://doi.org/10.18093/0869-0189-2020-30-4-473-484
Views:
709
Email this article 